7 completed, 1 terminated. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow cositecan: new trials by email Literature Review of cositecan trials Research Report on cositecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Karenitecin, Topotecan - Ovarian Cancer | Phase 3 | Completed | BioNumerik Pharmaceuticals, Inc. | 509 | 2007-08-01 | 2020-03-12 |
| Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma Karenitecin, Valproic Acid - Malignant Melanoma | Phase 1 / Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 42 | 2005-03-01 | 2013-11-25 |
| Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer Karenitecin (BNP1350) - Carcinoma, Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | BioNumerik Pharmaceuticals, Inc. | 32 | 2004-05-01 | 2020-03-12 |
| Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Cositecan, Pharmacological Study - Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 27 | 2003-01-01 | 2017-07-13 |
| Study of Karenitecin (BNP1350) to Treat Malignant Melanoma Karenitecin (BNP1350) - Melanoma, Neoplasm | Phase 2 | Completed | BioNumerik Pharmaceuticals, Inc. | 46 | 2002-05-01 | 2020-03-12 |
| Karenitecin in Treating Patients With Recurrent Malignant Glioma karenitecin - Brain and Central Nervous System Tumors | Phase 1 | Completed | National Cancer Institute (NCI) | 2002-01-01 | 2008-07-24 | |
| Study of Karenitecin (BNP1350) in Patients With Brain Tumors Karenitecin (BNP1350) - Brain Neoplasms, Malignant Neoplasms, Brain | Phase 2 | Completed | BioNumerik Pharmaceuticals, Inc. | 40 | 2001-10-01 | 2020-03-12 |
| Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer karenitecin - Lung Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 55 | 2001-04-01 | 2016-07-19 |
Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Astrocytoma (1) · Carcinoma (1) · Central Nervous System Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Oligodendroglioma (1)
BioNumerik Pharmaceuticals, Inc. (4) · Alliance for Clinical Trials in Oncology (1) · Gynecologic Oncology Group (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · National Cancer Institute (NCI) (1)
United States (7) · Hungary (1) · Lithuania (1) · Poland (1) · Romania (1) · Russia (1)
Adil Daud, M.D. (1) · Antonius A. Miller, MD (1) · John Kavanagh (1) · Stuart A. Grossman, MD (1)
U10CA027469 (1), U10CA031946 (1)